Literature DB >> 6206224

Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine.

C P France, A E Jacobson, J H Woods.   

Abstract

Pigeons were trained under a multiple-trial procedure to discriminate morphine (5.6 mg/kg) from saline. Morphine, oxymorphazone and buprenorphine each occasioned complete drug-appropriate responding in a dose-related manner and, at larger doses, suppressed responding completely. The order of potency as discriminative stimuli was buprenorphine greater than oxymorphazone greater than morphine; the potencies in suppressing responding were oxymorphazone greater than morphine greater than buprenorphine. Pretreatment with naltrexone (0.01-1.0 mg/kg) shifted the discrimination dose-effect curves to the right for all three compounds. When a discriminative effect was first established with morphine or oxymorphazone, the subsequent administration of naltrexone (0.01-0.32 mg/kg) completely and dose dependently antagonized the cue produced by each. Thus, oxymorphazone was not markedly different from morphine in its profile of action. Naltrexone up to 10.0 mg/kg failed to reverse completely the established discriminative effects of 0.32 mg/kg of buprenorphine, indicating that buprenorphine acts as an irreversible, morphine-like agonist in this behavioral situation. Buprenorphine had a much longer duration of action (3-4 days) than morphine (24 hr) or oxymorphazone (24-48 hr). Neither prolonged exposure to buprenorphine nor treatment with 100.0 mg/kg/day of morphine for 5 days produced tolerance to the discriminative or rate-suppressing effects of morphine. Buprenorphine also failed to antagonize either the discriminative or rate-suppressing effects of morphine. These data clearly demonstrate the irreversible morphine-like discriminative effects of buprenorphine and the reversible actions of morphine and oxymorphazone. These results also indicate that drug discrimination procedures may be valuable for the identification and characterization of irreversible agonists and antagonists.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206224

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Eating high-fat chow increases the sensitivity of rats to quinpirole-induced discriminative stimulus effects and yawning.

Authors:  Michelle G Baladi; Charles P France
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

2.  Tolerance to morphine stimulus control: role of morphine maintenance dose.

Authors:  A M Young; C A Sannerud; E S Steigerwald; M D Doty; W J Lipinski; L E Tetrick
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

5.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.

Authors:  Lenka Hruba; Lance R McMahon
Journal:  Eur J Pharmacol       Date:  2014-01-30       Impact factor: 4.432

7.  Evidence for perceptual masking of the discriminative morphine stimulus.

Authors:  D V Gauvin; A M Young
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Comparing single and cumulative dosing procedures in human triazolam discriminators.

Authors:  B J Smith; W K Bickel
Journal:  J Exp Anal Behav       Date:  1999-05       Impact factor: 2.468

Review 9.  Drug discrimination by humans compared to nonhumans: current status and future directions.

Authors:  J B Kamien; W K Bickel; J R Hughes; S T Higgins; B J Smith
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations.

Authors:  Thomas M Tzschentke
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.